Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 16/20 | 0.47 |
| ▸ | CDK2 | P24941 | 16/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11297942 | 0.81 | LMNA (0.35) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL11304047 | 0.80 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKAPAK1 | |
| SCHEMBL13439763 | 0.78 | HDAC3 (0.41) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL1909349 | 0.73 | ELANE (0.35) | — | |
| SCHEMBL428589 | 0.73 | ELANE (0.33) | — | |
| SCHEMBL12330009 | 0.72 | CCNA2 (0.48) | CCNA2CDK2CCNA1AURKAPAK1 | |
| SCHEMBL11306472 | 0.70 | CDK2 (0.49) | CCNA2CDK2CCNA1AURKAPAK1 | |
| SCHEMBL19359632 | 0.70 | MAPK1 (0.43) | CCNA2CDK2CCNA1AURKAPAK1 | |
| SCHEMBL11299560 | 0.69 | CDK2 (0.44) | CCNA2CDK2CCNA1AURKAPAK1 | |
| SCHEMBL13592001 | 0.67 | CDK2 (0.46) | CCNA2CDK2CCNA1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CCNA2 725/4885CDK2 65/4885CCNA1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.